<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00542126</url>
  </required_header>
  <id_info>
    <org_study_id>GnRHFETsupport.CTIL</org_study_id>
    <nct_id>NCT00542126</nct_id>
  </id_info>
  <brief_title>Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supraphysiological hormonal stimulation enables collecting many oocytes in an In-Vitro
      Fertilization treatment, but may have a negative effect on uterine function and contribute
      the fact that the majority of preembryos placed in the uterus fail to implant.

      Several medical agents were shown to be beneficial when given in the luteal phase of an IVF
      cycle, but the optimal regimen has not been yet determined. In 2006, a European group
      reported that addition of GnRH analog (Decapeptyl) as luteal support in IVF cycle
      significantly improved pregnancy and delivery rates. It is not known whether this positive
      effect influences the corpus luteum, embryo or the uterus. The researchers sought to evaluate
      the effect of GnRH administration as luteal support in frozen-thaws IVF cycle.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">September 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pregnancy and delivery rates</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Pregnancy Rate</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH analog administration following embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decapeptyl 0.1 mg after embryo transfer</intervention_name>
    <description>Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        IVF patients transfer of a minimum of two medium-quality thawed embryos in IVF

        Exclusion Criteria:

          1. Two or more fresh IVF embryo transfer or three or more thawed embryos transfer with no
             pregnancy.

          2. maximal endometrial thickness &lt; 6 mm or intracavitary fluid at the time of embryo
             transfer on previous cycles

          3. Untreated hydrosalpinges

          4. intracavitary mass

          5. submucous myoma

          6. known allergy to one of medical agents used in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avi Tsafrir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare-Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avi Tsafrir, MD</last_name>
    <phone>972-508573805</phone>
    <email>avits@scmz.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ehud Margalioth, MD</last_name>
    <email>ehudMD@scmz.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVF unit, Shaare-Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avi Tsafrir, MD</last_name>
      <phone>972-508573805</phone>
      <email>avits@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Avi Tsafrir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. Epub 2006 Aug 22.</citation>
    <PMID>16926261</PMID>
  </reference>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2007</study_first_posted>
  <last_update_submitted>October 9, 2007</last_update_submitted>
  <last_update_submitted_qc>October 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2007</last_update_posted>
  <keyword>GnRH analog, IVF, infertility, frozen-thawed embryos</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

